DOCSLIB.ORG

Opioid Peptides: Molecular Pharmacology, Biosynthesis, and Analysis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Opioid Peptides: Molecular Pharmacology, Biosynthesis, and Analysis U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol, Drug Abuse, and Mental Health Administration Opioid Peptides: Molecular Pharmacology, Biosynthesis, and Analysis Editors: Rao S. Rapaka, Ph.D. Richard L. Hawks, Ph.D. Division of Preclinical Research National Institute on Drug Abuse NIDA Research Monograph 70 1986 DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse 5600 Fishers Lane Rockville, Maryland 20857 NIDA Research Monographs are prepared by the research divisions of the National Institute on Drug Abuse and published by its Office of Science. The primary objective of the series is to provide critical reviews of research problem areas and techniques, the content of state-of-the-art conferences, and integrative research reviews. Its dual publication emphasis is rapid and targeted dissemination to the scientific and professional community Editorial Advisors MARTIN W. ADLER, Ph.D. SIDNEY COHEN, M.D. Temple University School of Medicine Los Angeles, California Philadelphia, Pennsylvania SYDNEY ARCHER, Ph.D. MARY L. JACOBSON Rensselaer Polytechnic Institute National Federation of Parents for Troy, New York Drug Free Youth RICHARD E. BELLEVILLE, Ph.D. Omaha, Nebraska NB Associates Health Sciences Rockville, Maryland REESE T. JONES, M.D. KARST J. BESTEMAN Langley Porter Neuropsychiatric Institute Alcohol and Drug Problems Association San Francisco, California of North America Washington, D.C. DENISE KANDEL, Ph.D. GILBERT J. BOTVIN, Ph.D. College of Physicians and Surgeons of Cornell University Medical College Columbia University New York, New York New York, New York JOSEPH V. BRADY, Ph.D. The Johns Hopkins University School of HERBERT KLEBER, M.D. Medicine Yale University School of Medicine Baltimore, Maryland New Haven, Connecticut THEODORE J. CICERO, Ph.D. Washington University School of RICHARD RUSSO Medicine New Jersey State Department of Health St. Louis, Missouri Trenton, New Jersey NIDA Research Monograph Series CHARLES R. SCHUSTER, Ph.D. Director, NIDA JEAN PAUL SMITH, Ph.D. Acting Associate Director for Science, NIDA Acting Editor Parklawn Building, 5600 Fishers Lane, Rockville, Maryland 20857 Opioid Peptides: Molecular Pharmacology, Biosynthesis, and Analysis ACKNOWLEDGMENT This monograph is based upon papers and discussion from the technical review on the medicinal chemistry and molecular pharmacology of opioid peptides and the opiates which took place on September 4 - 6, 1984, at Bethesda, Maryland. The meeting was sponsored by the Office of Science and the Division of Preclinical Research, National Institute on Drug Abuse. The papers on molecular pharmacology, biosynthesis, and analysis are presented in this volume. Those on the medicinal chemistry of opioid peptides appear in NIDA Research Monograph 69. COPYRIGHT STATUS The diagram on the cover of this volume is reprinted by permission from Camerman et al. Crystal structure of leucine-enkephalin. Nature 306:447-450. Copyright 1983, Macmillan Journals Limited. The National Institute on Drug Abuse has also obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprintlng of the entire publication or chapter. For any other use, the copyright holder's permission is required. All other material In this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors. Citation of the source is appreciated. Opinions expressed in this volume are those of the authors and do not necessarily reflect the opinions or official policy of the National Institute on Drug Abuse or any other part of the U.S. Department of Health and Human Services. The U.S. Government does not endorse or favor any specific commercial product or company. Trade, proprietary, or company names appearing in this publication are used only because they are considered essentlal in the context of the studies reported herein. DHHS Publication No. (ADM)87-1455 Alcohol, Drug Abuse, and Mental Health Administration Printed 1986 Reprinted 1987 NIDA Research Monographs are Indexed in the Index Medicus. They are selectively included in the coverage of American Statistics Index, Biosciences Information Service, Chemical Abstracts, Current Contents, Psychological Abstracts, and Psychopharmacology Abstracts. iv Foreword The discovery of opioid peptides in the mid-seventies came at an opportune time, as all the technologies required for identification and synthesis of opioid peptides were readily available. The identification of opioid genes followed shortly, facilitated by recent advances in recombinant technology. This in turn led to the rapid identification of many more opioid peptides. Concurrently, recognition of opioid receptor heterogeneity brought to the fore questions about the role of the multiple receptors in analgesia and abuse liability. Another area of research which quickly developed following these discoveries was the analysis of opioid peptides in Diofluids, a difficult area which presents unique problems due to the low levels present. Most analytical development has been based on radioimmunoassays, which are quite sensitive but which suffer from variable specificities. Development of chemical methods that are both specific and sensitive has been urgently needed, particularly in anticipation of the development of peptides for clinical trials and the need to have adequate pharmacokinetic analyses of such drugs. This volume is primarily concerned with the molecular pharmacology, biosynthesis, and analysis of the opioid peptides. It is the companion volume to NIDA Research Monograph 69, Opioid Peptides: Medicinal Chemistry. We stand at an exciting point in this rapidly expanding field. It is hoped that this volume and the preceding one will serve as useful reference sources for researchers and will provide new incentives for drug abuse research in the opioid peptide field. Marvin Snyder, Ph.D., Director Division of Preclinical Research National Institute on Drug Abuse v Contents Foreword Marvin Snyder. v Introduction Rao S. Rapaka. 1 Folding and Enzymatic Processing of Precursors of Biologically Active Peptides and Proteins Irwin M. Chaiken; Tatsuhiko Kanmera; and Reginald P. Sequeira . 3 Biosynthesis of Opioid Peptides Olivier Civelli; Jim Douglass; Haim Rosen; Gerard Martens; and Edward Herbert . 21 Proenkephalin Biosynthesis in the Rat Richard D. Howells . 43 Enzymes in the Metabolism of Opioid Peptides: Isolation, Assay, and Specificity Neville Marks; Myron Benuck; and Martin J. Berg . 66 Isolation and Identification of Opioid Peptides Hisayuki Matsuo . 92 B-Endorphin: Naturally Occurring or Synthetic Agonists and Antagonists Choh Hao Li . .109 Enkephalin Degrading Enzyme Inhibitors: A Physiological Way to New Analgesics and Psychoactive Agents Bernard P. Roques and Marie-Claude Fournie-Zaluski . 128 Progress in the Characterization of the Opioid Receptor Subtypes: Peptides as Probes. Future Directions Eric J. Simon. 155 Regulation of Agonist Binding to Opioid Receptor Types by Sodium and GTP: Relevance to Receptor Function Brian M. Cox; Linda L. Werling; and Gary Zarr . 175 Opioid Receptors for the Dynorphin Peptides Iaian F. James . , . 192 vii Computer Analysis of Radioligand Data: Advantages, Problems, and Pitfalls David Rodbard; Rudolph A. Lutz; Ricardo A. Cruciani; Vincenzo Guardabasso; Guido 0. Pesce; and Peter J. Munson . 209 Recent Developments in Bioassay Using Selective Ligands and Selective In Vitro Preparations Hans W. Kosterlitz; Alistair D. Corbett; Maureen G. C. Gillan; Alexander T. McKnight; Stewart J. Paterson; and Linda E. Robson . 223 Endorphins and Memory Regulation Ivan Izquierdo; Carlos A. Netto; and Renato D. Dias . 237 Current Status of RIA Methods for the Analysis of Enkephalins and Endorphins R. Wayne Hendren. 255 The Analysis of Endogenous Opioid Peptides With HPLC, Radioreceptor Assay, Radioimunoassay, and Mass Spectrometry Dominic M. Desiderio; Hisayoshi Takeshita; Hiroshi Onishi; Genevieve Fridland; Francis S. Tanzer; Claire Wakelyn; and Chhabil Dass. 304 Reverse Phase HPLC of Peptides: Application to the Opioid Peptides Tatsuhiko Kanmera and Reginald P. Sequeira . 319 Peptides as Drugs in the Treatment of Opiate Addiction Hemendra N. Bhargava . 337 Progress in the Potential Use of Enkephalin Analogs Robert C. A. Frederickson. 367 Opioid Peptides as Drug Products: FDA Regulatory Requirements Charles P. Hoiberg and Rao S. Rapaka . 385 A Few Thoughts on the Development and Regulation of Neuropeptides John L. Gueriguian and Yuan-Yuan H. Chiu. 405 viii Introduction Rao S. Rapaka, Ph.D. In order to bring into focus the rapidly expanding areas of research associated with the opioid peptides, the National Institute on Drug Abuse sponsored a technical review in September 1984 on the medicinal chemistry and molecular pharmacology of opioid peptides and the opiates. As stated in the introduction to NIDA Research Monograph 69, a companion volume to NIDA Research Monograph 70, this is an area of major interest for both the short-term and long-term goals of the Institute because of its potential usefulness in further research and in treatment applications. This monograph presents contributions both from the symposium speakers and from other invited
Recommended publications
  • Docteur» at the University François Rabela

    Docteur» at the University François Rabela

    UNIVERSITÉ FRANÇOIS – RABELAIS DE TOURS École Doctorale « Santé - Sciences Biologiques - Chimie du Vivant » and UNIVERSITY OF LJUBLJANA, FACULTY OF PHARMACY «Department of Pharmaceutical Chemistry» A cotutelle thesis submitted in fulfillment of the requirements for the degree of «Docteur» at the University François Rabelais of Tours (France) and Doctor of Pharmacy at the University of Ljubljana (Slovenia) In Pharmaceutical Chemistry Publicly defended on the 1st of March 2013 by Mitja KOVAČ in Ljubljana FLUORATION DE DERIVES DU BENZOVESAMICOL POUR L'OBTENTION DE RADIOLIGANDS POTENTIELS DU TRANSPORTEUR VESICULAIRE DE L'ACETYLCHOLINE Under the co-direction of: Associate Professor Sylvie Mavel (MCU, Tours) and Associate Professor Marko Anderluh (Ljubljana) ----------------- JURY for Oral Defense: Ms MAVEL Sylvie – Associate Professor, University François-Rabelais, Tours, France Mr ANDERLUH Marko – Associate Professor, University of Ljubljana, Slovenia Mr DOLLÉ Frédéric – Service Hospitalier Frédéric Joliot, Institut d'Imagerie BioMédicale - CEA, Orsay, France (Reviewer) Mr EMOND Patrick – Professor, University François-Rabelais, Tours, France Ms GMEINER STOPAR Tanja – Assistant Professor, University of Ljubljana, Slovenia (Reviewer) Mr GOBEC Stanislav – Professor, University of Ljubljana, Slovenia (Chairman) This cotutelle PhD was carried out with the collaboration between the University of Tours (Laboratoire de Biophysique Médicale et Pharmaceutique, Unité INSERM U930 - FRANCE) and the University of Ljubljana (Faculty of Pharmacy, Department of Pharmacutical Chemistry - SLOVENIA). The work was supported by a grant from the Slovene Human Resources Development and Scholarship Fund, by a grant from the University of Ljubljana (Inovativna shema za sofinanciranje doktorskega študija za spodbujanje sodelovanja z gospodarstvom in reševanja aktualnih družbenih izzivov - generacija 2010 Univerza v Ljubljani), and by a Slovenia- French bilateral collaboration project (project n° BI-FR/12-13-PROTEUS-007).
  • An Immortalized Myocyte Cell Line, HL-1, Expresses a Functional D

    An Immortalized Myocyte Cell Line, HL-1, Expresses a Functional D

    J Mol Cell Cardiol 32, 2187–2193 (2000) doi:10.1006/jmcc.2000.1241, available online at http://www.idealibrary.com on An Immortalized Myocyte Cell Line, HL-1, Expresses a Functional -Opioid Receptor Claire L. Neilan1, Erin Kenyon1, Melissa A. Kovach1, Kristin Bowden1, William C. Claycomb2, John R. Traynor3 and Steven F. Bolling1 1Department of Cardiac Surgery, University of Michigan, B558 MSRB II, Ann Arbor, MI 48109-0686, USA, 2Department of Biochemistry and Molecular Biology, Louisiana State University Medical Center, New Orleans, LA 70112, USA and 3Department of Pharmacology, University of Michigan, 1301 MSRB III, Ann Arbor, MI 48109-0632, USA (Received 17 March 2000, accepted in revised form 30 August 2000, published electronically 25 September 2000) C. L. N,E.K,M.A.K,K.B,W.C.C,J.R.T S. F. B.An Immortalized Myocyte Cell Line, HL-1, Expresses a Functional -Opioid Receptor. Journal of Molecular and Cellular Cardiology (2000) 32, 2187–2193. The present study characterizes opioid receptors in an immortalized myocyte cell line, HL-1. Displacement of [3H]bremazocine by selective ligands for the mu (), delta (), and kappa () receptors revealed that only the -selective ligands could fully displace specific [3H]bremazocine binding, indicating the presence of only the -receptor in these cells. Saturation binding studies with the -antagonist naltrindole 3 afforded a Bmax of 32 fmols/mg protein and a KD value for [ H]naltrindole of 0.46 n. The binding affinities of various ligands for the receptor in HL-1 cell membranes obtained from competition binding assays were similar to those obtained using membranes from a neuroblastoma×glioma cell line, NG108-15.
  • Analytical Performance of an Immunoassay to Measure Proenkephalin ⁎ Leslie J

    Analytical Performance of an Immunoassay to Measure Proenkephalin ⁎ Leslie J

    Clinical Biochemistry xxx (xxxx) xxx–xxx Contents lists available at ScienceDirect Clinical Biochemistry journal homepage: www.elsevier.com/locate/clinbiochem Analytical performance of an immunoassay to measure proenkephalin ⁎ Leslie J. Donatoa, ,Jeffrey W. Meeusena, John C. Lieskea, Deborah Bergmannc, Andrea Sparwaßerc, Allan S. Jaffea,b a Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, United States b Division of Cardiology, Mayo Clinic, Rochester, MN 55905, United States c Sphingotec GmbH, Hennigsdorf, Germany ARTICLE INFO ABSTRACT Keywords: Background: Endogenous opioids, enkephalins, are known to increase with acute kidney injury. Since the mature Biomarkers pentapeptides are unstable, we evaluated the performance of an assay that measures proenkephalin 119–159 Proenkephalin (PENK), a stable peptide formed concomitantly with mature enkephalins. Enkephalin Methods: PENK assay performance was evaluated on two microtiterplate/chemiluminescence sandwich im- Pro-enkephalin munoassay formats that required 18 or 1 h incubation times. PENK concentration was measured in plasma from penKid healthy individuals to establish a reference interval and in patients with varied levels of kidney function and Assay validation comorbidities to assess the association with measured glomerular filtration rate (mGFR) using iothalamate clearance. Results: Assay performance characteristics in plasma were similar between the assay formats. Limit of quanti- tation was 26.0 pmol/L (CV = 20%) for the 1 h assay and 17.3 pmol/L (CV = 3%) for the 18 h assay. Measurable ranges were 26–1540 pmol/L (1 h assay) and 18–2300 pmol/L (18 h assay). PENK concentrations are stable in plasma stored ambient to 10 days, refrigerated to at least 15 days, and frozen to at least 90 days.
  • Design and Synthesis of Cyclic Analogs of the Kappa Opioid Receptor Antagonist Arodyn

    Design and Synthesis of Cyclic Analogs of the Kappa Opioid Receptor Antagonist Arodyn

    Design and synthesis of cyclic analogs of the kappa opioid receptor antagonist arodyn By © 2018 Solomon Aguta Gisemba Submitted to the graduate degree program in Medicinal Chemistry and the Graduate Faculty of the University of Kansas in partial fulfillment of the requirements for the degree of Doctor of Philosophy. Chair: Dr. Blake Peterson Co-Chair: Dr. Jane Aldrich Dr. Michael Rafferty Dr. Teruna Siahaan Dr. Thomas Tolbert Date Defended: 18 April 2018 The dissertation committee for Solomon Aguta Gisemba certifies that this is the approved version of the following dissertation: Design and synthesis of cyclic analogs of the kappa opioid receptor antagonist arodyn Chair: Dr. Blake Peterson Co-Chair: Dr. Jane Aldrich Date Approved: 10 June 2018 ii Abstract Opioid receptors are important therapeutic targets for mood disorders and pain. Kappa opioid receptor (KOR) antagonists have recently shown potential for treating drug addiction and 1,2,3 4 8 depression. Arodyn (Ac[Phe ,Arg ,D-Ala ]Dyn A(1-11)-NH2), an acetylated dynorphin A (Dyn A) analog, has demonstrated potent and selective KOR antagonism, but can be rapidly metabolized by proteases. Cyclization of arodyn could enhance metabolic stability and potentially stabilize the bioactive conformation to give potent and selective analogs. Accordingly, novel cyclization strategies utilizing ring closing metathesis (RCM) were pursued. However, side reactions involving olefin isomerization of O-allyl groups limited the scope of the RCM reactions, and their use to explore structure-activity relationships of aromatic residues. Here we developed synthetic methodology in a model dipeptide study to facilitate RCM involving Tyr(All) residues. Optimized conditions that included microwave heating and the use of isomerization suppressants were applied to the synthesis of cyclic arodyn analogs.
  • Characterisation and Partial Purification of a Novel Prohormone Processing Enzyme from Ovine Adrenal Medulla

    Characterisation and Partial Purification of a Novel Prohormone Processing Enzyme from Ovine Adrenal Medulla

    Volume 246, number 1,2, 44-48 FEB 06940 March 1989 Characterisation and partial purification of a novel prohormone processing enzyme from ovine adrenal medulla N. Tezapsidis and D.C. Parish Biochemistry Group, School of Biological Sciences, University of Sussex, Falmer, Brighton, Sussex, England Received 3 January 1989 An enzymatic activity has been identified which is capable of generating a product chromatographically identical with adrenorphin from the model substrate BAM 12P. This enzyme was purified by gel filtration and ion-exchange chromatog- raphy and characterised as having a molecular mass between 30 and 45 kDa and an acidic pL The enzyme is active at the acid pH expected in the secretory vesicle interior and is inhibited by EDTA, suggesting that it is a metalloprotease. This activity could not be mimicked by incubation with lysosomal fractions and it meets the criteria to be considered as a possible prohormone processing enzyme. Prohormone processing; Adrenorphin; Secretory vesiclepurification 1. INTRODUCTION The purification of an endopeptidase responsi- ble for the generation of adrenorphin was under- Active peptide hormones are released from their taken, using the ovine adrenal medulla as a source. precursors by endoproteolytic cleavage at highly Adrenorphin is known to be located in the adrenal specific sites. The commonest of these is cleavage medulla of all species so far investigated [6]. at pairs of basic residues such as lysine and Secretory vesicles (also known as chromaffin arginine [1,2]. However another common class of granules) were isolated as a preliminary purifica- processing sites are known to be at single arginine tion step, since it is known that prohormone pro- residues, adjacent to a proline [3].
  • Information to Users

    Information to Users

    The direct and modulatory antinociceptive actions of endogenous and exogenous opioid delta agonists Item Type text; Dissertation-Reproduction (electronic) Authors Vanderah, Todd William. Publisher The University of Arizona. Rights Copyright © is held by the author. Digital access to this material is made possible by the University Libraries, University of Arizona. Further transmission, reproduction or presentation (such as public display or performance) of protected items is prohibited except with permission of the author. Download date 04/10/2021 00:14:57 Link to Item http://hdl.handle.net/10150/187190 INFORMATION TO USERS This ~uscript }las been reproduced from the microfilm master. UMI films the text directly from the original or copy submitted. Thus, some thesis and dissertation copies are in typewriter face, while others may be from any type of computer printer. The quality of this reproduction is dependent upon the quality of the copy submitted. Broken or indistinct print, colored or poor quality illustrations and photographs, print bleedthrough, substandard margins, and improper alignment can adversely affect reproduction. In the unlikely. event that the author did not send UMI a complete mannscript and there are missing pages, these will be noted Also, if unauthorized copyright material had to be removed, a note will indicate the deletion. Oversize materials (e.g., maps, drawings, charts) are reproduced by sectioning the original, beginnjng at the upper left-hand comer and contimJing from left to right in equal sections with small overlaps. Each original is also photographed in one exposure and is included in reduced form at the back of the book. Photographs included in the original manuscript have been reproduced xerographically in this copy.
  • Download Product Insert (PDF)

    Download Product Insert (PDF)

    PRODUCT INFORMATION Dynorphin A Item No. 18169 CAS Registry No.: 80448-90-4 O O Formal Name: dynorphin A HO NH2 HO NH O O NH2 Synonym: Dynorphin A (1-17) O N O H C H N O H O NH MF: 99 155 31 23 N O O H H H N NH FW: 2,147.5 N N 2 N N N H H O O NH O O H H H H N N N ≥95% H2N H2N O Purity: N N NH NH H H O O O NH O H N Stability: ≥2 years at -20°C O N H2N N N H NH2 H H O NH2 Supplied as: A crystalline solid OH UV/Vis.: λmax: 279 nm Laboratory Procedures For long term storage, we suggest that dynorphin A be stored as supplied at -20°C. It should be stable for at least two years. Dynorphin A is supplied as a crystalline solid. A stock solution may be made by dissolving the dynorphin A in the solvent of choice. Dynorphin A is soluble in organic solvents such as DMSO and dimethyl formamide, which should be purged with an inert gas. The solubility of dynorphin A in these solvents is approximately 30 mg/ml. Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of dynorphin A can be prepared by directly dissolving the crystalline solid in aqueous buffers.
  • Genscript Product Catalog 2013-2014 Genscript Product Catalog

    Genscript Product Catalog 2013-2014 Genscript Product Catalog

    GenScript Product Catalog 2013-2014 GenScript Product Catalog www.genscript.com GenScript USA Inc. 860 Centennial Ave. Piscataway, NJ 08854USA Tel: 1-732-885-9188 / 1-732-885-9688 Toll-Free Tel: 1-877-436-7274 Fax: 1-732-210-0262 / 1-732-885-5878 Email: [email protected] Nucleic Acid Purification and Analysis Business Development Tel: 1-732-317-5088 PCR PCR and Cloning Email: [email protected] Protein Analysis Antibodies 2013-2014 Peptides Welcome to GenScript GenScript USA Incorporation, founded in 2002, is a fast-growing biotechnology company and contract research organization (CRO) specialized in custom services and consumable products for academic and pharmaceutical research. Built on our assembly-line mode, one-stop solutions, continuous improvement, and stringent IP protection, GenScript provides a comprehensive portfolio of products and services at the most competitive prices in the industry to meet your research needs every day. Over the years, GenScript’s scientists have developed many innovative technologies that allow us to maintain our position at the cutting edge of biological and medical research while offering cost-effective solutions for customers to accelerate their research. Our advanced expertise includes proprietary technology for custom gene synthesis, OptimumGeneTM codon optimization technology, CloneEZ® seamless cloning technology, FlexPeptideTM technology for custom peptide synthesis, BacPowerTM technology for protein expression and purification, T-MaxTM adjuvant and advanced nanotechnology for custom antibody production, as well as our ONE-HOUR WesternTM detection system and eStain® protein staining system. GenScript offers a broad range of reagents, optimized kits, and system solutions to help you unravel the mysteries of biology. We also provide a comprehensive portfolio of customized services that include Bio-Reagent, Bio-Assay, Lead Optimization, and Antibody Drug Development which can be effectively integrated into your value chain and your operations.
  • Rubsicolins Are Naturally Occurring G-Protein-Biased Delta Opioid Receptor Peptides

    Rubsicolins Are Naturally Occurring G-Protein-Biased Delta Opioid Receptor Peptides

    bioRxiv preprint doi: https://doi.org/10.1101/433805; this version posted October 5, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Title page Title: Rubsicolins are naturally occurring G-protein-biased delta opioid receptor peptides Short title: Rubsicolins are G-protein-biased peptides Authors: Robert J. Cassell1†, Kendall L. Mores1†, Breanna L. Zerfas1, Amr H.Mahmoud1, Markus A. Lill1,2,3, Darci J. Trader1,2,3, Richard M. van Rijn1,2,3 Author affiliation: 1Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, 2Purdue Institute for Drug Discovery, 3Purdue Institute for Integrative Neuroscience, West Lafayette, IN 47907 †Robert J Cassell and Kendall Mores contributed equally to this work Corresponding author: ‡Richard M. van Rijn, Department of Medicinal Chemistry and Molecular Pharmacology, College of Pharmacy, Purdue University, West Lafayette, Indiana 47907 (Phone: 765-494- 6461; Email: [email protected]) Key words: delta opioid receptor; beta-arrestin; natural products; biased signaling; rubisco; G protein-coupled receptor Abstract: 187 Figures: 2 Tables: 2 References: 27 1 bioRxiv preprint doi: https://doi.org/10.1101/433805; this version posted October 5, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract The impact that β-arrestin proteins have on G-protein-coupled receptor trafficking, signaling and physiological behavior has gained much appreciation over the past decade. A number of studies have attributed the side effects associated with the use of naturally occurring and synthetic opioids, such as respiratory depression and constipation, to excessive recruitment of β-arrestin.
  • Design & Synthesis of Polycyclic Amine Derivatives for Sigma Receptor Activity

    Design & Synthesis of Polycyclic Amine Derivatives for Sigma Receptor Activity

    UNIVERSITY OF THE WESTERN CAPE Design & Synthesis of Polycyclic Amine derivatives for Sigma Receptor Activity Natasha Strydom February 2013 Supervisor: Prof. S.F. Malan Co-Supervisor: Dr. J. Joubert A thesis submitted in partial fulfilment of the requirements for the degree of Magister Scientiae in the Department of Natural Sciences, University of the Western Cape. KEYWORDS Polycyclic amine Pentacycloundecane Amantadine Heterocyclic amines Sigma receptor Neurodegeneration Drug addiction Blood brain permeability Drug Design Ligand based Structure activity relationship i ABSTRACT New therapeutic strategies are needed for a diverse array of poorly understood neurological impairments. These include neurodegenerative disorders such as Parkinson’s disease and Alzheimer’s disease, and the psychiatric disorders such as depression, anxiety and drug dependence. Popular neuropharmacotherapies have focused on dopamine (DA), serotonin (5HT), γ-aminobutric acid (GABA) and glutamate systems (Jupp & Lawrence, 2010). However recent research points to the sigma receptor (σR) as a possible neuromodulatory system. Due to its multi-receptor action, the σR can trigger several significant biological pathways. This indicates its ideal potential as a drug target to effectively minimise drug dosage and potential side effects. Currently there are a limited number of σR ligands available and few possess the selectivity to significantly show σR’s role in neurological processes. Polycyclic amines have shown notable sigma activity and provide an advantageous scaffold for drug design that can improve pharmacodynamic and pharmacokinetic properties (Banister et al., 2010; Geldenhuys et al., 2005). Aryl-heterocycle amine groups were also shown to improve σR activity (Piergentili et al., 2009). A series of pentacycloundecane compounds were synthesised which aimed at evaluating the inclusion of a amine containing aryl group in the design compared to previous pentacycloundecane structures containing only two lipophilic regions.
  • Opioid Receptorsreceptors

    Opioid Receptorsreceptors

    OPIOIDOPIOID RECEPTORSRECEPTORS defined or “classical” types of opioid receptor µ,dk and . Alistair Corbett, Sandy McKnight and Graeme Genes encoding for these receptors have been cloned.5, Henderson 6,7,8 More recently, cDNA encoding an “orphan” receptor Dr Alistair Corbett is Lecturer in the School of was identified which has a high degree of homology to Biological and Biomedical Sciences, Glasgow the “classical” opioid receptors; on structural grounds Caledonian University, Cowcaddens Road, this receptor is an opioid receptor and has been named Glasgow G4 0BA, UK. ORL (opioid receptor-like).9 As would be predicted from 1 Dr Sandy McKnight is Associate Director, Parke- their known abilities to couple through pertussis toxin- Davis Neuroscience Research Centre, sensitive G-proteins, all of the cloned opioid receptors Cambridge University Forvie Site, Robinson possess the same general structure of an extracellular Way, Cambridge CB2 2QB, UK. N-terminal region, seven transmembrane domains and Professor Graeme Henderson is Professor of intracellular C-terminal tail structure. There is Pharmacology and Head of Department, pharmacological evidence for subtypes of each Department of Pharmacology, School of Medical receptor and other types of novel, less well- Sciences, University of Bristol, University Walk, characterised opioid receptors,eliz , , , , have also been Bristol BS8 1TD, UK. postulated. Thes -receptor, however, is no longer regarded as an opioid receptor. Introduction Receptor Subtypes Preparations of the opium poppy papaver somniferum m-Receptor subtypes have been used for many hundreds of years to relieve The MOR-1 gene, encoding for one form of them - pain. In 1803, Sertürner isolated a crystalline sample of receptor, shows approximately 50-70% homology to the main constituent alkaloid, morphine, which was later shown to be almost entirely responsible for the the genes encoding for thedk -(DOR-1), -(KOR-1) and orphan (ORL ) receptors.
  • Receptor Types

    Receptor Types

    Proc. Natl. Acad. Sci. USA Vol. 87, pp. 3180-3184, April 1990 Pharmacology Chimeric opioid peptides: Tools for identifying opioid receptor types (dynorphin/dermorphin/deltorphin/monoclonal antibody/panning) Guo-xi XIE*t, ATSUSHI MIYAJIMA*, TAKASHI YOKOTA*, KEN-ICHI ARAI*, AND AVRAM GOLDSTEINt *Department of Molecular Biology, DNAX Research Institute of Molecular and Cellular Biology, Palo Alto, CA 94304; and tDepartment of Pharmacology, Stanford University, Stanford, CA 94305 Contributed by Avram Goldstein, January 23, 1990 ABSTRACT We synthesized several chimeric peptides in was assumed that the C-terminal amide group ofdermorphin, which the N-terminal nine residues of dynorphin-32, a peptide deltorphins, and DSLET and the alcohol group of DAGO selective for the K opioid receptor, were replaced by opioid could be removed without affecting opioid binding. By anal- peptides selective for other opioid receptor types. Each chi- ogy to dyn-32, which binds selectively to K opioid sites, meric peptide retained the high affminty and type selectivity DAGO-DYN and dermorphin-DYN should bind selectively characteristic of its N-terminal sequence. The common C- to p.; deltorphins-DYN and DSLET-DYN should bind selec- terminal two-thirds of the chimeric peptides served as an tively to 8. mAbs 17.M and 39 should act as nonblocking epitope recognized by the same monoclonal antibody. When antibodies to all these peptides. bound to receptors on a cell surface or membrane preparation, In the present study, we have demonstrated that the these peptides could still bind specifically to the monoclonal chimeric peptides do maintain the high affinities and type antibody. These chimeric peptides should be useful for isolating selectivities of their N-terminal sequences.